258 related articles for article (PubMed ID: 15486072)
1. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Faderl S; Gandhi V; O'Brien S; Bonate P; Cortes J; Estey E; Beran M; Wierda W; Garcia-Manero G; Ferrajoli A; Estrov Z; Giles FJ; Du M; Kwari M; Keating M; Plunkett W; Kantarjian H
Blood; 2005 Feb; 105(3):940-7. PubMed ID: 15486072
[TBL] [Abstract][Full Text] [Related]
2. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Faderl S; Verstovsek S; Cortes J; Ravandi F; Beran M; Garcia-Manero G; Ferrajoli A; Estrov Z; O'Brien S; Koller C; Giles FJ; Wierda W; Kwari M; Kantarjian HM
Blood; 2006 Jul; 108(1):45-51. PubMed ID: 16403905
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
[TBL] [Abstract][Full Text] [Related]
4. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
6. Biochemical modulation of cytarabine triphosphate by clofarabine.
Cooper T; Ayres M; Nowak B; Gandhi V
Cancer Chemother Pharmacol; 2005 Apr; 55(4):361-368. PubMed ID: 15723262
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
8. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine.
Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Kantarjian H; Gandhi V; Cortes J; Verstovsek S; Du M; Garcia-Manero G; Giles F; Faderl S; O'Brien S; Jeha S; Davis J; Shaked Z; Craig A; Keating M; Plunkett W; Freireich EJ
Blood; 2003 Oct; 102(7):2379-86. PubMed ID: 12791647
[TBL] [Abstract][Full Text] [Related]
11. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Burnett AK; Russell NH; Hills RK; Kell J; Nielsen OJ; Dennis M; Cahalin P; Pocock C; Ali S; Burns S; Freeman S; Milligan D; Clark RE
Leukemia; 2017 Feb; 31(2):310-317. PubMed ID: 27624670
[TBL] [Abstract][Full Text] [Related]
12. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
[TBL] [Abstract][Full Text] [Related]
13. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Cooper T; Kantarjian H; Plunkett W; Gandhi V
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1417-23. PubMed ID: 15571270
[TBL] [Abstract][Full Text] [Related]
15. Clofarabine combinations as acute myeloid leukemia salvage therapy.
Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
[TBL] [Abstract][Full Text] [Related]
16. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
17. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
18. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
Faderl S; Balakrishnan K; Thomas DA; Ravandi F; Borthakur G; Burger J; Ferrajoli A; Cortes J; O'Brien S; Kadia T; Feliu J; Plunkett W; Gandhi V; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):231-8. PubMed ID: 24440659
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
20. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
